MA29141B1 - Pyrrolopyrazoles, servant de puissants inhibiteurs de kinases - Google Patents

Pyrrolopyrazoles, servant de puissants inhibiteurs de kinases

Info

Publication number
MA29141B1
MA29141B1 MA30059A MA30059A MA29141B1 MA 29141 B1 MA29141 B1 MA 29141B1 MA 30059 A MA30059 A MA 30059A MA 30059 A MA30059 A MA 30059A MA 29141 B1 MA29141 B1 MA 29141B1
Authority
MA
Morocco
Prior art keywords
kinases
pyrrolopyrazoles
inhibitors
powerful inhibitors
compounds
Prior art date
Application number
MA30059A
Other languages
English (en)
Inventor
Djamal Bouzida
Liming Dong
Chuangxing Guo
Yufeng Hong
Haitao Li
Joseph Timothy Marakovits
Anle Yang
Junhu Zhang
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA29141B1 publication Critical patent/MA29141B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

L'INVENTION DES COMPOSÉS DE PYRROLOPYRAZOLES DE FORMULE (I), DES COMPOSITIONS COMPRENANT LESDITS COMPOSÉS, AINSI QUE LEURS MÉTHODES D'UTILISATION. LES COMPOSÉS PRÉFÉRÉS DE FORMULE I PRÉSENTENT UNE ACTIVITÉ EN TANT QU'INHIBITEURS DE PROTÉINES KINASES, NOTAMMENT EN TANT QU'INHIBITEURS DE PAK4.
MA30059A 2005-01-10 2007-07-10 Pyrrolopyrazoles, servant de puissants inhibiteurs de kinases MA29141B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64290005P 2005-01-10 2005-01-10
US73377005P 2005-11-04 2005-11-04

Publications (1)

Publication Number Publication Date
MA29141B1 true MA29141B1 (fr) 2008-01-02

Family

ID=36463340

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30059A MA29141B1 (fr) 2005-01-10 2007-07-10 Pyrrolopyrazoles, servant de puissants inhibiteurs de kinases

Country Status (29)

Country Link
US (2) US8067591B2 (fr)
EP (1) EP1838718B1 (fr)
JP (1) JP4250195B2 (fr)
KR (1) KR100919343B1 (fr)
CN (1) CN101115760B (fr)
AP (1) AP2007004061A0 (fr)
AT (1) ATE512972T1 (fr)
AU (1) AU2005323797B2 (fr)
BR (1) BRPI0518509A2 (fr)
CA (1) CA2593428C (fr)
CU (1) CU23778B7 (fr)
CY (1) CY1111752T1 (fr)
DK (1) DK1838718T3 (fr)
EA (1) EA011815B1 (fr)
ES (1) ES2365245T3 (fr)
GE (1) GEP20094785B (fr)
HR (1) HRP20110485T1 (fr)
IL (1) IL184275A0 (fr)
MA (1) MA29141B1 (fr)
MX (1) MX2007008385A (fr)
NO (1) NO20073859L (fr)
NZ (1) NZ556273A (fr)
PL (1) PL1838718T3 (fr)
PT (1) PT1838718E (fr)
RS (1) RS51891B (fr)
SI (1) SI1838718T1 (fr)
TN (1) TNSN07254A1 (fr)
WO (1) WO2006072831A1 (fr)
ZA (1) ZA200705628B (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ568692A (en) 2005-12-21 2011-07-29 Pfizer Prod Inc Carbonylamino pyrrolopyrazoles, potent kinase inhibitors
CN101646673B (zh) * 2007-02-07 2014-06-25 辉瑞大药厂 作为pkc抑制剂的3-氨基-吡咯并[3,4-c]吡唑-5(1h,4h,6h)甲醛衍生物
CA2677572C (fr) 2007-02-07 2012-12-18 Pfizer Inc. Nouveaux derives de 3-amino-pyrrolo[3,4-c]pyrazole-5(1h,4h,6h) carbaldehyde
AU2008237660B2 (en) 2007-04-12 2011-12-22 Pfizer Inc. 3-amido-pyrrolo [3, 4-C] pyrazole-5 (1H, 4H, 6H) carbaldehyde derivatives as inhibitors of protein kinase C
US8415340B2 (en) 2007-07-25 2013-04-09 Bristol-Myers Squibb Company Triazine kinase inhibitors
FR2928150A1 (fr) 2008-02-29 2009-09-04 Vetoquinol Sa Sa Nouveaux derives 7-substitues de 3-carboxy-oxadiazino-quinolones, leur preparation et leur application comme anti-bacteriens
WO2009130900A1 (fr) * 2008-04-24 2009-10-29 日本曹達株式会社 Dérivé d’oxime, composé intermédiaire et agent de lutte contre des maladies végétales
EP2145891A1 (fr) 2008-07-09 2010-01-20 Vetoquinol S.A. Dérivés de 9-substitués-5-carboxy-oxadiazino-quinolone, leur préparation et leur application en tant qu'antibactériens
WO2011044264A2 (fr) * 2009-10-06 2011-04-14 Afraxis, Inc. Pyrrolopyrazoles pour le traitement de troubles du snc
KR101483215B1 (ko) * 2010-01-29 2015-01-16 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체
WO2012065935A1 (fr) 2010-11-17 2012-05-24 F. Hoffmann-La Roche Ag Méthodes de traitement de tumeurs
AR088218A1 (es) 2011-07-19 2014-05-21 Infinity Pharmaceuticals Inc Compuestos heterociclicos utiles como inhibidores de pi3k
WO2013113720A1 (fr) 2012-02-03 2013-08-08 Basf Se Composés de pyrimidine fongicides
WO2013113787A1 (fr) 2012-02-03 2013-08-08 Basf Se Composés de pyrimidine fongicides
AU2013214137A1 (en) 2012-02-03 2014-08-21 Basf Se Fungicidal pyrimidine compounds
WO2013113778A1 (fr) 2012-02-03 2013-08-08 Basf Se Composés de pyrimidine fongicides
WO2013113782A1 (fr) 2012-02-03 2013-08-08 Basf Se Composés de pyrimidine fongicides
WO2013113716A1 (fr) 2012-02-03 2013-08-08 Basf Se Composés de pyrimidine fongicides
WO2013113773A1 (fr) 2012-02-03 2013-08-08 Basf Se Composés fongicides de pyrimidine
WO2013113719A1 (fr) 2012-02-03 2013-08-08 Basf Se Composés de pyrimidine fongicides ii
WO2013113781A1 (fr) 2012-02-03 2013-08-08 Basf Se Composés de pyrimidine fongicides i
WO2013113776A1 (fr) 2012-02-03 2013-08-08 Basf Se Composés de pyrimidine fongicides
AU2013214353A1 (en) 2012-02-03 2014-08-21 Basf Se Fungicidal pyrimidine compounds
WO2013135672A1 (fr) 2012-03-13 2013-09-19 Basf Se Composés de pyrimidine fongicides
EP2825533B1 (fr) 2012-03-13 2016-10-19 Basf Se Composés pyrimidiniques fongicides
JP2015511598A (ja) 2012-03-16 2015-04-20 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｐａｋ１阻害剤を用いて黒色腫を治療する方法
AU2013318283A1 (en) 2012-09-19 2015-03-05 Novartis Ag Dihydropyrrolidino-pyrimidines as kinase inhibitors
IN2015DN02877A (fr) * 2012-10-15 2015-09-11 Pfizer Ireland Pharmaceuticals
CA2923101A1 (fr) 2013-09-16 2015-03-19 Basf Se Composes pyrimidines fongicides
WO2015036059A1 (fr) 2013-09-16 2015-03-19 Basf Se Composés fongicides de pyrimidine
JP6854762B2 (ja) 2014-12-23 2021-04-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤
USRE50776E1 (en) 2015-03-27 2026-02-03 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
MX394157B (es) 2015-06-15 2025-03-24 Ube Corp Derivado de dihidropirrolopirazol sustituido.
CN104926735A (zh) * 2015-06-16 2015-09-23 上海合全药物研发有限公司 4-氯-5-氟-2-甲基嘧啶的工业化制备方法
SG11201804901WA (en) 2015-12-22 2018-07-30 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
WO2017144546A1 (fr) 2016-02-23 2017-08-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques pour le traitement d'un carcinome de rhinopharyngite
AU2017363307B2 (en) 2016-11-22 2021-07-29 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof
EA201992780A1 (ru) 2017-06-21 2020-06-02 ШАЙ ТЕРАПЬЮТИКС ЭлЭлСи Соединения, которые взаимодействуют с суперсемейством ras, для лечения рака, воспалительных заболеваний, ras-опатий и фиброзного заболевания
CA3097543A1 (fr) * 2018-04-16 2019-10-24 The Regents Of The University Of California Inhibiteurs de pak4 et procedes d'utilisation
EP3810132A4 (fr) 2018-06-25 2022-06-22 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinase de la famille taire et utilisations correspondantes
US12391705B2 (en) 2018-12-19 2025-08-19 Shy Therapeutics, Llc Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
US12281126B2 (en) 2018-12-28 2025-04-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
EP3956446A1 (fr) 2019-04-17 2022-02-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés et compositions de traitement de troubles dépendants de il-1beta mediés par inflamasome nlrp3
CN118767143A (zh) 2019-12-12 2024-10-15 听治疗有限责任公司 用于预防和治疗听力损失的组合物和方法
WO2021198511A1 (fr) 2020-04-03 2021-10-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pour le traitement d'une infection par sars-cov-2
CN111454278B (zh) * 2020-05-15 2021-03-19 四川大学 Pak1抑制剂及其合成和在制备抗肿瘤药物中的应用
WO2022008597A1 (fr) 2020-07-08 2022-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et composition pharmaceutique pour le traitement de maladies infectieuses
CN121248675A (zh) * 2020-12-31 2026-01-02 赛诺哈勃药业（成都）有限公司 一种纤溶酶抑制剂、其制备方法及应用
WO2024261302A1 (fr) 2023-06-22 2024-12-26 Institut National de la Santé et de la Recherche Médicale Inhibiteurs de nlrp3, inhibiteurs de pak1/2 et/ou inhibiteurs de caspase 1 pour le traitement de maladies monogéniques liées au rac2
WO2025078334A1 (fr) 2023-10-09 2025-04-17 Institut National de la Santé et de la Recherche Médicale Combinaison d'inhibiteurs de pak1 et d'inhibiteurs de clk pour prévenir la résistance à la chimiothérapie chez des patients souffrant de leucémie myéloïde aiguë

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3423414A (en) * 1966-01-13 1969-01-21 Ciba Geigy Corp Pyrazolopyridines
US3526633A (en) * 1968-03-06 1970-09-01 American Cyanamid Co Substituted 2,4,5,6-tetrahydropyrrolo(3,4-c)pyrazoles
US3947467A (en) * 1973-08-02 1976-03-30 Eli Lilly And Company 3-(5-Nitro-2-imidazolyl) pyrazoles
JPS5163193A (ja) 1974-11-26 1976-06-01 Yoshitomi Pharmaceutical Tetorahidoropirazoropirijinkagobutsuno seizoho
US6013500A (en) * 1998-05-21 2000-01-11 The Trustees Of Columbia University In The City Of New York PAK4, a novel gene encoding a serine/threonine kinase
DK1320531T3 (da) 2000-08-10 2011-01-03 Pfizer Italia Srl Bicyclo-pyrazoler, der er aktive som kinase inhibitorer, fremgangsmåde til fremstilling deraf og farmaceutiske sammensætninger, der indeholder disse
CA2493637A1 (fr) * 2002-07-25 2004-02-12 Manuela Villa Bicyclo-pyrazoles actifs inhibiteurs de kinase, procede de preparation et compositions pharmaceutiques contenant ceux-ci
UA81790C2 (uk) * 2002-12-19 2008-02-11 Фармация Италия С.П.А. Заміщені піролопіразольні похідні як інгібітори кінази
US7141568B2 (en) * 2003-07-09 2006-11-28 Pfizer Italia S.R.L. Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them

Also Published As

Publication number Publication date
AU2005323797B2 (en) 2009-07-09
KR100919343B1 (ko) 2009-09-25
US20100222342A1 (en) 2010-09-02
PT1838718E (pt) 2011-08-17
US8530652B2 (en) 2013-09-10
PL1838718T3 (pl) 2011-10-31
US20120264751A1 (en) 2012-10-18
DK1838718T3 (da) 2011-07-25
IL184275A0 (en) 2007-10-31
CA2593428A1 (fr) 2006-07-13
CU23778B7 (es) 2012-02-15
RS51891B (sr) 2012-02-29
AU2005323797A1 (en) 2006-07-13
CA2593428C (fr) 2012-04-17
TNSN07254A1 (en) 2008-12-31
HK1114380A1 (en) 2008-10-31
CU20070160A7 (es) 2009-03-16
EP1838718A1 (fr) 2007-10-03
EP1838718B1 (fr) 2011-06-15
JP4250195B2 (ja) 2009-04-08
HRP20110485T1 (hr) 2011-07-31
CN101115760A (zh) 2008-01-30
US8067591B2 (en) 2011-11-29
KR20070096007A (ko) 2007-10-01
ES2365245T3 (es) 2011-09-27
NO20073859L (no) 2007-10-03
CN101115760B (zh) 2010-11-03
EA011815B1 (ru) 2009-06-30
NZ556273A (en) 2010-01-29
ATE512972T1 (de) 2011-07-15
AP2007004061A0 (en) 2007-08-31
MX2007008385A (es) 2007-08-21
GEP20094785B (en) 2009-09-25
ZA200705628B (en) 2008-11-26
WO2006072831A1 (fr) 2006-07-13
EA200701257A1 (ru) 2007-12-28
CY1111752T1 (el) 2015-10-07
JP2008526826A (ja) 2008-07-24
BRPI0518509A2 (pt) 2008-11-25
SI1838718T1 (sl) 2011-08-31

Similar Documents

Publication Publication Date Title
MA29141B1 (fr) Pyrrolopyrazoles, servant de puissants inhibiteurs de kinases
TNSN05208A1 (fr) Composes aminoheteroaryliques servant d'inhibiteurs de proteine-kinases
MA30784B1 (fr) Derives phenyliques et utilisation de ceux-ci en tant qu'immunomodulateurs.
GEP20104974B (en) Carbonylamino pyrrolopyrazoles, protent kinase inhibitors
JO3181B1 (ar) مشتقات كمحول ثاني الكيل البايردينيل - أحادي الفينيل كأنزيم ثنائي استرات الفوسفود
NO20070557L (no) Ftalazinderivater som PARP-inhibitorer
ATE433447T1 (de) Pyrimiidinverbindungen
NO20041493L (no) Kjemiske forbindelser.
MA27467A1 (fr) Quinolones anti-microbiens, leurs compositions et utilisations
NO20070529L (no) Kinazolindionderivater som parp-inhibitorer
NO20070866L (no) Antivirale forbindelser.
BR0313176A (pt) Composições de pirazol úteis como inibidores de gsk-3
MA31683B1 (fr) Composes et procedes pour moduler fxr
TW200719892A (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the same
NO20075992L (no) Forbindelser som modulerer C-Kit og C-FMS aktivitet og anvendelser derav
ATE430747T1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
MA31919B1 (fr) Composés inhibiteurs de la dipeptidyl peptidase-iv, leurs procédés de préparation, et compositions pharmaceutiques contenant ces composés comme agent actif
DK1789398T3 (da) 2-amino-quinazolin derivater anvendelige som inhibitorer af B-sekretase (BACE)
BRPI0512352A (pt) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimiocinas
MA32173B1 (fr) Derives de pyridin-2-yle utilises comme agents immunomodulateurs
MA29723B1 (fr) Composes
MA31526B1 (fr) Nouveaux herbicides
NO20065051L (no) Bazedoksifenacetat faste dispersjonsfomuleringer
NO20080839L (no) Isotopsubstituerte protonpumpeinhibitorer
MY145765A (en) Anthracenedione compounds